Yasunori Iwao

Prof. Yasunori Iwao

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2023 in ACS Nano
Verified
Journal Article
Closed access
KYKengo Yasuda
Kengo Yasuda
HMHitoshi Maeda
Hitoshi Maeda
RKRyo Kinoshita
Ryo Kinoshita
YMYuki Minayoshi
Yuki Minayoshi
YMYuki Mizuta
Yuki Mizuta
TMToru Maruyama
Toru Maruyama

11 January 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
TFTatsuya Fukuta
Tatsuya Fukuta
MIMayumi Ikeda
Mayumi Ikeda
SKSatoshi Kodama
Satoshi Kodama
JKJunko Kuse
Junko Kuse
KMKo Matsui
Ko Matsui
YIYasunori Iwao
Yasunori Iwao
The use of exosomes encapsulating therapeutic agents for the treatment of diseases is of increasing interest. However, some concerns such as limited efficiency and scalability of conventional drug encapsulation methods to exosomes have still remained; thus, a new approach that enables encapsulation of therapeutic agents with superior efficiency and scalability is required. Herein, we used RAW264 macrophage cell-derived exosomes (RAW-Exos) and demonstrated that high-pressure homogenization (HPH) using a microfluidizer decreased their particle size without changing their morphology, the amount of exosomal marker proteins, and cellular uptake efficiency into RAW264 and colon-26 cancer cells. Moreover, HPH allowed for modification of polyethylene glycol (PEG)-conjugated lipids onto RAW-Exos, as well as encapsulation of the anti-cancer agent doxorubicin. Importantly, the doxorubicin encapsulation efficiency became higher upon increasing the process pressure and simultaneous HPH with PEG-lipids. Moreover, treatment with PEG-modified RAW-Exos encapsulating doxorubicin significantly suppressed tumor growth in colon-26-bearing mice. Taken together, these results suggest that HPH using a microfluidizer could be useful to prepare PEG-modified Exos encapsulating anti-cancer drugs via a one-step pharmaceutical process, and that the prepared functional Exos could be applied for the treatment of cancer in vivo.

8 May 2023 in Molecular Pharmaceutics
Verified
Journal Article
Open access
TFTatsuya Fukuta
Tatsuya Fukuta
MIMayumi Ikeda-Imafuku
Mayumi Ikeda-Imafuku
YIYasunori Iwao
Yasunori Iwao
Preparation of the ionic liquid (IL) form of active pharmaceutical ingredients (APIs), termed API-IL, has attracted attention because it can improve upon certain disadvantages of APIs, such as poor water solubility and low stability. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) is a clinically approved cerebroprotective agent against ischemic stroke and amyotrophic lateral sclerosis, while new formulations that enable improvement of its physicochemical properties and biodistribution are desired. Herein, we report a newly developed API-IL of edaravone (edaravone-IL), in which edaravone is used as an anionic molecule. We investigated the physicochemical properties of edaravone-IL and its therapeutic effect against cerebral ischemia/reperfusion (I/R) injury, a secondary injury after an ischemic stroke. Among the cationic molecules used for edaravone-IL preparation, the IL prepared with tetrabutylphosphonium cation existed as a liquid at room temperature, and significantly increased the water solubility of edaravone without decreasing its antioxidative activity. Importantly, edaravone-IL formed negatively charged nanoparticles upon suspension in water. Intravenous administration of edaravone-IL showed significantly higher blood circulation time and lower distribution in the kidney compared with edaravone solution. Moreover, edaravone-IL significantly suppressed brain cell damage and motor functional deficits in model rats of cerebral I/R injury and showed comparable cerebroprotective effect to edaravone. Taken together, these results suggest that edaravone-IL could be a new form of edaravone with superior physicochemical properties and could be useful for the treatment of cerebral I/R injury.

1 May 2013 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
YIYasunori Iwao
Yasunori Iwao
STShoko Tanaka
Shoko Tanaka
TUTakeaki Uchimoto
Takeaki Uchimoto
SNShuji Noguchi
Shuji Noguchi
SIShigeru Itai
Shigeru Itai

1 March 2011 in Drug Metabolism and Disposition
Verified
Journal Article
Open access
PDF file
KTKazuaki Taguchi
Kazuaki Taguchi
YIYasunori Iwao
Yasunori Iwao
Hiroshi WatanabeHiroshi Watanabe
Hiroshi Watanabe
DKDaisuke Kadowaki
Daisuke Kadowaki
HSHiromi Sakai
Hiromi Sakai
Masaki OtagiriMasaki Otagiri
Masaki Otagiri
The hemoglobin vesicle (HbV) is an artificial oxygen carrier in which a concentrated hemoglobin solution is encapsulated in a liposome. To apply liposome preparations in clinics, it is important to consider the accelerated blood clearance phenomenon (ABC phenomenon), which involves a loss in the long-circulation half-life after being administered repeatedly to the same animals. The objective of this study was to determine whether the ABC phenomenon is induced by repeated injection of HbV under conditions of hemorrhagic shock. We created a rat model of hemorrhagic shock and performed a pharmacokinetic study using 125I-HbV, in which the Hb inside of HbV was labeled with 125I. At 4 and 7 days after resuscitation from hemorrhagic shock by nonlabeled HbV (1400 mg Hb/kg), the second dose of 125I-HbV (1400 mg Hb/kg) was rapidly cleared from the circulation compared with normal rats. Of interest, IgM against HbV was produced at 4 days after the first injection of HbV, but decreased at 7 days. In addition, phagocyte activity was increased at both 4 and 7 days after the first injection of HbV. These results suggest that repeated injections of HbV at a dose of 1400 mg Hb/kg induce the ABC phenomenon under conditions of hemorrhagic shock, which is strongly related to both the production of anti-HbV IgM and enhanced phagocyte activity. We thus conclude that it might be necessary to considerer the ABC phenomenon in the dose regimen of HbV treatment in clinical settings.

1 April 2015 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
ABAhmad Bani-Jaber
Ahmad Bani-Jaber
AKAsuka Kobayashi
Asuka Kobayashi
KYKyohei Yamada
Kyohei Yamada
DHDana Haj-Ali
Dana Haj-Ali
TUTakeaki Uchimoto
Takeaki Uchimoto
SIShigeru Itai
Shigeru Itai